Loading
A phase 1/2 trial of atamparib escalation levels in non-small-cell lung cancer, run by Nerviano Medical Sciences (Shanghai) Ltd., now recruiting.
Atamparib in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07374419 by Nerviano Medical Sciences (Shanghai) Ltd., with 178 participants planned, started 2026-03-18 and due to reach its primary completion in 2028-07-31. Interventions recorded: atamparib escalation levels and atamparib RP2D.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Nerviano Medical Sciences and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/